Infliximab for the treatment of refractory scleritis

British Journal of Ophthalmology

Volumn 94, Issue 5, 2010, Pages 579-583

  Doctor, Priyanka ^a,b   Sultan, Amyna ^a   Syed, Sana ^a   Christen, William ^c,d   Bhat, Pooja ^a   Foster, C Stephen ^a,c,e  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b BayView Clinic   (India)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Massachusetts Eye Research and Surgery Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CELECOXIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIFLUNISAL; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TRIAMCINOLONE ACETONIDE; VALACICLOVIR;

ABSENCE OF SIDE EFFECTS; ARTICLE; BEHCET DISEASE; CROHN DISEASE; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; GASTRITIS; HERPES ZOSTER; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; NAUSEA; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RETINA MACULA CYSTOID EDEMA; RHEUMATOID ARTHRITIS; SCLERITIS; SIDE EFFECT; VISUAL ACUITY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SCLERITIS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VISUAL ACUITY;

EID: 77952149370     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.150961     Document Type: Article

References (15)

1. Benson WE. Posterior scleritis. Surv Ophthalmol 1988;32:297-316.
2. Sainz de la Maza M, Jabbur NS, Foster CS. An analysis of therapeutic decision for scleritis. Ophthalmology 1993;100:1372-1376
3. Soukiasian SH, Foster CS, Raizman MB. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol 1994;118:601-611 (Pubitemid 24345621)
4. Kim EC, Foster CS. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. Int Ophthalmol Clin 2006;46:141-164
5. Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 1998;10:397-422. (Pubitemid 28525336)
6. Valesini G, Iannuccelli C, Marocchi E, et al. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007;7:35-41. (Pubitemid 47633389)
7. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol 1976;60: 163-191
8. Mease P. Infliximab (Remicade) in the treatment of psoriatic arthritis. Ther Clin Risk Manag 2006;2:389-400. (Pubitemid 44895990)
9. Lamprecht P, Till A, Steinmann J, et al. Current state of biologicals in the management of systemic vasculitis. Ann N Y Acad Sci 2007;1110:261-270 (Pubitemid 350043015)
10. Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007;125:895-900. (Pubitemid 47076425)
11. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007;27:399-413.
12. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-912 (Pubitemid 41057986)
13. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008;37:381-387 (Pubitemid 351734520)
14. Marques M, Magro F, Cardoso H, et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 2007; 14:723-725
15. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;1: CD006893.